Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 2, 2009, Pages 400-408

  Eker, Salih Saygin ^a   Kirli, Selcuk ^a   Akkaya, Cengiz ^a   Cangur, Sengul ^a   Sarandol, Asli ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Antidepressants; Depression; Gender

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; REBOXETINE; SEROTONIN AGONIST; SERTRALINE; VENLAFAXINE; ADRENERGIC RECEPTOR AFFECTING AGENT; CYCLOHEXANOL DERIVATIVE; MORPHOLINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; REMISSION; AGE; CLIMACTERIUM; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; MAJOR DEPRESSION; MIDDLE AGED; PERSONALITY TEST; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; CLIMACTERIC; CLINICAL TRIALS AS TOPIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; MORPHOLINES; PERSONALITY INVENTORY; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; YOUNG ADULT;

EID: 77449098829     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970903131886     Document Type: Article

References (76)

1. .IscanN Ozbay H. 1996. Hamilton Depresyon Derecelendirme Olcegi (HDDO)'nin gecerligi-gu-venirligi ve klinikte kullanimi (Validity-reliability and clinical use of Turkish version of Hamilton depression rating scale). Psikiyatri Psikol Psikofarmakol Derg 4 251-259.
2. Akkaya C, Sivrioglu Y, Sarandol A, Kirli S. 2003. Major depre-sif bozuklukta venlafaksin XR ve reboksetin'in etkililik ve guvenilirliginin karsilastirilmasi (Comparison of venlafaxine XR and reboxetine in terms of efficacy and safety in Major Depressive Disorder). Yeni Symposium 41:170-177.
3. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association.
4. Amin Z, Canli T, Epperson CN. 2005. Effect of estrogen-serotonin interactions on mood and cognition. Behav Cogn Neurosci Rev 4:43-58.
5. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, et al. 1999. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord 55:11-17.
6. Ayuso-Gutierrez JL. 2005. Depressive subtypes and efficacy of antidepressive pharmacotherapy. World J Biol Psychiatry 6: 31-37.
7. Baca E, Garcia-Garcia M, Porras-Chavarino A. 2004. Gender differences in treatment response to sertraline versus imipra-mine in patients with nonmelancholic depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry 28:57-65.
8. Ballus C, Quiros G, De Flores, de la Torre J, Palao D, Rojo L, et al. 2000. Int Clin Psychopharmacol 15:43-48
9. Bano S, Akhter S, Afridi MI. 2004. Gender based response to fluoxetine hydrochloride medication in endogenous depression. J Coll Phys Surg Pak 14:161-165.
10. Bebbington PE, Dunn G, Jenkins R, Lewis G, Brugha T, Farrell M, et al. 1998. The influence of age and sex on the prevalence of depressive conditions: Report from the National Survey of Psychiatric Comorbidity. Psychol Med 28:9-19.
11. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. 1975. Quantitative rating of depressive states. Acta Psychiatr Scand 51:161-170.
12. Berlanga C, Flores-Ramos M. 2006. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 95:119-123.
13. Bowden CL, Schatzberg AF, Rosenbaum A, Contreras SA, Samson JA, Dessain E, et al. 1993. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 13:305-310.
14. Carlsson M, Carlsson A. 1988. A regional study of sex differences in rat brain serotonin. Prog Neuropsychopharmacol Biol Psychiatry 12:53-61.
15. Chugani DC, Muzik O, Chakraborty P, Mangner T, Chugani HT. 1998. Human brain serotonin synthesis capacity measured in vivo with alpha-[C-11]methyl-L- tryptophan. Synapse 28:33-43.
16. Cohen LS, Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL. 2003. Short term use of estradiol for depression on perimenopausal and postmenopausal women: A preliminary report. Am J Psychiatry 160:1519-1522.
17. Crowley WR, Filicori M. 1985. The physiology of GnRH secretion in man and woman. Recent Prog Horm Res 41:473-531.
18. Cyr M, Bosse R, Di Paolo T 1998. Gonadal hormones modulate 5-hydroxytryptamine2A receptors: Emphasis on the rat frontal cortex. Neuroscience 83:829-836.
19. De Nayer A, Geerts S, Ruelens L, Schittecatte M, Bleeker E, Van Eeckhoutte I, et al. 2002. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 5:115-120.
20. DeJonghe F, Ravelli DP, Tuynmna-Qua H. 1991. A randomized, double blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 24:62-67.
21. Dickinson SL, Curzon G. 1986. 5-Hydroxytryptamine-mediated behavior in male and female rats. Neuropharmacology 25:771-776.
22. Eker SS, Akkaya C, Akgoz S, Sarandol A, Kirli S. 2005. Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder. Turk Psikiyatri Derg 16:153-163.
23. Ellenbogen MA, Young SN, Dean P, Palmour RM, Benkelfat C. 1996. Mood response to acute tryptophan depletion in healthy volunteers: Sex differences and temporal stability. Neuropsy-chopharmacology 15:465-474
24. Entsuah AR, Huang H, Thase ME. 2001. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 62:869-877.
25. Fink G, Sumner BE, Rosie R, Grace O, Quinn JP. 1996. Estrogen control of central neurotransmission: Effect on mood, mental state and memory. Cell Mol Neurobiol 16:325-344.
26. Grigoriadis S, Kennedy SH, Bagby RM. 2003. A comparison of antidepressant response in younger and older women. J Clinl Psychopharmacol 23:405-407
27. Goodwin RD, Gotlib IH. 2004. Gender differences in depression: The role of personality factors. Psychiatry Res 126:135-142.
28. Guy W 1976. ECDEU Assessment Manual for Psychopharma-cology. Revised US Dept Health, Education and Welfare publication (ADM). Rockville, MD: National Institute of Mental Health.
29. Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH. 2004. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: Pharmacological and clinical profile. CNS Drug Rev 10:23-44.
30. Halbreich U, Rojansky N, Palter S, Tworek H, Hissin P, Wang K. 1995. Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry 37:434-441.
31. Haleem DJ, Kennett GA, Curzon G. 1990. Hippocampal 5-hydroxytryptamine synthesis is greater in female rats than in males and more decreased by the 5-HT agonist 8-OH-DPAT J Neural Transm 79:93-101.
32. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
33. Harvey AT, Rudolph RL, Preskorn SH. 2000. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 57:503-509.
34. Healy D, McMonagle T 1997. The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol 11:25-31.
35. Herbison AE. 1997. Noradrenergic regulation of cyclic GnRH secretion. Rev Reprod 2:1-6.
36. Heritage AS, Grant ID, Stumpf WE. 1977. 3H estradiol in catecholamine neurons of rat brain stem: combined localisation by autoradiographic and formaldehyde-induced fluorescence. J Comp Neurol 176:607-630.
37. Hildebrandt MG, Steverberg EW, Stage KB, Psschier J, Kragh-Soerensen P, Danish University Antidepressant Group. 2003. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 160:1643-1650.
38. Hirschfeld RM, Klerman GL, Clayton PJ, Keller MB, Andreasen NC. 1984. Personality and gender-related differences in depression. J Affect Disord 7:211-221.
39. Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbot RM, et al. 2002. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust NZ J Psychiatry 36:384-391.
40. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. 1993. A longitudinal twin study of 1-year prevalence of major depression in women. Arch Gen Psychiatry 50:843-852.
41. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. 1994. Lifetime and 12-month prevalence of DSM-III-R-psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19.
42. Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA. 2005. Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol 25:318-324.
43. Kornstein SG. 1997. Gender differences in depression: implications for treatment. J Clin Psychiatry 58:12-18.
44. Kornstein SG, Schatzberg AE, Thase ME. 2000a. Gender differences in chronic major depression and double depression. J Affect Disord 60:1-11.
45. Kornstein SG, Schatzberg AF, Thase ME, Yonker KA, McCul-lough JP, Keitner GI, et al. 2000b. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 157:1445-1452.
46. Lepine JP, Caillard V, Bisserbe JC, Troy S, Hotton JM, Boyer P. 2004. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 161:836-842.
47. Martenyi F, Dossenbach M, Mraz K, Metcalfe S. 2001. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 11:227-232.
48. McEwen BS, Alves SE, Bulloch K, Weiland NG. 1997. Ovarian steroids and the brain: implications for cognition and aging. Neurology 48:8-15.
49. Montgomery SA. 1997. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 11:9-15.
50. Morrison MF, Kallan MJ, Have T, Katz I, Tweedy K, Battistini M. 2004. Lack of efficacy of estradiol for depression in postmenopausal women: A randomized, controlled trial. Biol Psychiatry 55:406-412
51. Morse DT 1999. Minsize2: a computer program for determining effect size and minimum sample size for statistical significance for univariate, multivariate, and nonparametric tests. Educ Psychol Meas 59:518.
52. Moller-Leimkuhler AM. 2008. Women with coronary artery disease and depression: a neglected risk group. World J Biol Psychiatry 9:92-101.
53. Naito S, Sato K, Yoshida K, Higuchi H, Takahashi H, Kamata M, et al. 2007. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients. Psychiatry Clin Neurosci 61:421-427
54. Nelson JC, Portera L, Leon AC. 2005a. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor? Biol Psychiatry 57:1535-1542.
55. Nelson JC, Portera L, Leon AC. 2005b. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. J Clin Psychiatry 66:1409-1414.
56. Neumeister A. 2003. Tryptophan depletion, serotonin, and depression: where do we stand? Psychopharmacol Bull 37:99-115.
57. Nishizawa S, Benkelfat C, Young SN, Leyton M, Mzengeza S, de Montigny C, et al. 1997. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci USA 94:5308-5313.
58. Nurnberg HG. 2008. An evidence-based review updating the various treatment and management approaches to serotonin reuptake inhibitor-associated sexual dysfunction. Drugs Today (Barc) 44:147-168.
59. Pjrek E, Konstantinidis A, Assem-Hilger E, Praschak-Rieder N, Willeit M, Kasper S, et al. 2009. Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: A pooled analysis. J Psychiatr Res 43:792-797.
60. Quitkin FM, Stewart JW, McGrath PJ, Taylor BP, Tisminetzky MS, Petkova E, et al. 2002. Are there differences between women's and men's antidepressant responses? Am J Psychiatry 159:1848-1854.
61. Raskin A. 1974. Age sex differences in response to antidepressant drugs. J Nerv Ment Dis 159:120-130.
62. Rubinow DR, Schmidt PJ, Roca CA. 1998. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 44:839-850.
63. Scates AC, Doraiswamy PM. 2000. Reboxetine: A selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 34:1302-1312.
64. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, et al. 2000. Estrogen replacement in perimeno-pause-related depression: A preliminary report. Am J Obstet Gynecol 183:414-420
65. Schneider LS, Small GW, Clary C. 2001. Estrogen replacement therapy and antidepressant response to sertraline. Am J Geriatr Psychiatry 9:393-399.
66. Schweizer E, Rynn M, Mandos LA, Demartinis N, Garcia-Espana F, Rickles K. 2001. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol 16:137-143.
67. Siegel S, Castellan NJ. 1988. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill.
68. Silverstein B. 1999. Gender difference in the prevalence of clinical depression: the role played by depression associated with somatic symptoms. Am J Psychiatry 156:480-482
69. Soares CN, Almeida OP, Joffe H, Cohen LS. 2001. Efficacy of estradiol for the treatment of depressive disorders in perime-nopausal women: A double-blind, randomized, placebo controlled trial. Arch Gen Psychiatry 58:529-534.
70. Soares CN, Poitras JR, Prouty J, Alexander AB, Shifren JL, Cohen LS. 2003. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry 64:473-479
71. Stahl SM, Entsuah R, Rudolph RL. 2002. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 52:1166-1174.
72. Sumner BE, Fink G. 1995. Estrogen increases the density of 5-hydroxytryptamine (2A) receptors in cerebral cortex and nucleus accumbens in the female rat. J Steroid Biochem Mol Biol 54:15-20.
73. Thase ME, Entsuah R, Cantillon M, Kormstein SG. 2005. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health 14:609-616.
74. Thiels C, Linden M, Grieger F, Leonard J. 2005. Gender differences in routine treatment of depressed outpatients with the selective serotonin reuptake inhibitor sertraline. Int Clin Psychopharmacol 20:1-7.
75. Yazicioglu B, Akkaya C, Sarandol A, Akgoz S, Eker SS, Kirli S. 2006. A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: A randomized, open-labeled clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 30:1271-1276.
76. Wang JL. 2004. The difference between single and married mothers in the 12-month prevalence of major depressive syndrome, associated factors and mental health service utilization. Soc Psychiatry Psychiatr Epidemiol 39:26-32.